Hereditary Cancer Syndromes: Are Your Patients at Risk?

Welcome to “Hereditary Cancer Syndromes: Are Your Patients at Risk?” This program was developed to help oncology providers identify, evaluate, and manage patients at increased risk of hereditary cancer syndromes. The program was developed by the Michigan State Department of Health and Human Services and The Jackson Laboratory Clinical and Continuing Education Program with funding from the Centers for Disease Control and Prevention.

Genetic testing is becoming increasingly accessible for patients as the list of clinical indications and number of genes are growing, and the cost of testing is decreasing. Identifying a patient with an underlying genetic variant associated with cancer can impact his or her treatment options, long-term management approach, and risks for other cancer. In addition, there are implications for close family members. While genetic testing can provide important clinical information for decision-making, there are benefits, limitations, and risks. This program focuses on developing skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan.

Learning Objectives

Upon completion of this educational activity, the learner will be able to:

• Determine if a patient is a candidate for cancer genetic testing
• Deliver pre-testing counseling appropriate to the patient
• Select the best genetic test for the patient
• Interpret genetic testing results
• Identify patient management based on genetic testing results

Target Audience

This activity is designed to meet the educational needs of practicing clinicians who work with cancer patients.

Dates, Duration & Fee

• Original Publication Date: 10/31/2019
• Renewal Date: 10/14/2021
• Estimated time to Complete: 2 hours
• Registration Fee: Free

Faculty, Planners, & Reviewers

Kate Reed, MPH, ScM, CGC - The Jackson Laboratory
Linda Steinmark, MS, CGC - The Jackson Laboratory
Emily Edelman, MS, CGC -  The Jackson Laboratory
Therese Ingram Nissen, MA -  The Jackson Laboratory
Angela Trepanier, MS, CGC  - Wayne State University School of Medicine
Aman Mann, MS, CGC - Northwell Health Cancer Institute
Sarah Austin, MS, CGC – Michigan Medicine
Elena Stoffel, MD, MPH – University of Michigan

Commercial Support

None

Financial Relationship Disclosure

This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest. Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course.

Hardware/Software Requirements

Screen resolution of 800X600 or higher

Adobe Reader 5.0 or higher 

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical and Continuing Education at the Jackson Laboratory.

References

American College of Medical Genetics and Genomics Board of Directors (2016). Direct-to-consumer genetic testing: a revised position statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 18(2), 207–208.

American College of Obstetrics and Gynecology (2019). Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793. Obstetrics and Gynecology, 134(6), e143–e149.

Baroutsou, V., Underhill-Blazey, M. L., Appenzeller-Herzog, C., & Katapodi, M. C. (2021). Interventions Facilitating Family Communication of Genetic Testing Results and Cascade Screening in Hereditary Breast/Ovarian Cancer or Lynch Syndrome: A Systematic Review and Meta-Analysis. Cancers, 13(4), 925.

Berliner, J. L., Cummings, S. A., Boldt Burnett, B., & Ricker, C. N. (2021). Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice Resource of the National Society of Genetic Counselors. Journal of Genetic Counseling, 30(2), 342–360.

Bijlsma, R. M., Wessels, H., Wouters, R., May, A. M., Ausems, M., Voest, E. E., & Bredenoord, A. L. (2018). Cancer patients' intentions towards receiving unsolicited genetic information obtained using next-generation sequencing. Familial Cancer, 17(2), 309–316.

Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., González-Neira, A., Luccarini, C., Wahlström, C., Pooley, K. A., Parsons, M. T., Fortuno, C., Wang, Q., Bolla, M. K., Dennis, J., Keeman, R., Alonso, M. R., Álvarez, N., Herraez, B., Fernandez, V., Núñez-Torres, R., Osorio, A., … Easton, D. F. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. NEJM, 384(5), 428–439.

Corso, G., & Magnoni, F. (2021). Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations. European Journal of Cancer. 30(4), 311–314.

DeLeonardis, K., Hogan, L., Cannistra, S. A., Rangachari, D., & Tung, N. (2019). When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing? Journal of Oncology Practice, 15(9), 465–473.

Eggert J. (2017). Genetics and Genomics in Oncology Nursing: What Does Every Nurse Need to Know? The Nursing Clinics of North America. 52(1), 1–25.

Giri, V. N., Knudsen, K. E., Kelly, W. K., Cheng, H. H., Cooney, K. A., Cookson, M. S., Dahut, W., Weissman, S., Soule, H. R., Petrylak, D. P., Dicker, A. P., AlDubayan, S. H., Toland, A. E., Pritchard, C. C., Pettaway, C. A., Daly, M. B., Mohler, J. L., Parsons, J. K., Carroll, P. R., Pilarski, R., … Gomella, L. G. (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 38(24), 2798–2811.

Haga, S. B., & Orlando, L. A. (2020). The enduring importance of family health history in the era of genomic medicine and risk assessment. Personalized Medicine, 17(3), 229–239. 

Hamilton, J. G., & Robson, M. E. (2019). Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. The Hastings Center Report, 49 Suppl 1(Suppl 1), S44–S52.

Heald, B., Hampel, H., Church, J., Dudley, B., Hall, M. J., Mork, M. E., Singh, A., Stoffel, E., Stoll, J., You, Y. N., Yurgelun, M. B., Kupfer, S. S., & Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (2020). Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Familial Cancer, 19(3), 223–239.

Jain, R., Savage, M. J., Forman, A. D., Mukherji, R., & Hall, M. J. (2016). The relevance of hereditary cancer risks to precision oncology: what should providers consider when conducting tumor genomic profiling? Journal of the National Comprehensive Cancer Network, 14(6), 795–806.

King, E., & Mahon, S. M. (2017). Genetic Testing: Challenges and Changes in Testing for Hereditary Cancer Syndromes. Clinical Journal of Oncology Nursing, 21(5), 589–598.

Kurian, A. W., Ward, K. C., Hamilton, A. S., Deapen, D. M., Abrahamse, P., Bondarenko, I., Li, Y., Hawley, S. T., Morrow, M., Jagsi, R., & Katz, S. J. (2018). Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncology, 4(8), 1066–1072.

Kurian, A. W., Griffith, K. A., Hamilton, A. S., Ward, K. C., Morrow, M., Katz, S. J., & Jagsi, R. (2017). Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. JAMA, 317(5), 531–534.

Mahon, S. (Accessed 2021, Aug 16). Why Oncology Nurses Need to Embrace Genetics. ONS Voice.  https://voice.ons.org/news-and-views/why-oncology-nurses-need-to-embrace-genetics

McReynolds, K. M., & Connors, L. M. (2019). Genomics of Prostate Cancer: What Nurses Need to Know. Seminars in Oncology Nursing, 35(1), 79–92.

Narod S. A. (2021). Which Genes for Hereditary Breast Cancer? NEJM, 384(5), 471–473.

National Comprehensive Cancer Network.  http://www.nccn.org

Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015). American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 33(31), 3660–3667.

Snyder, C., & Hampel, H. (2019). Hereditary Colorectal Cancer Syndromes. Seminars in Oncology Nursing, 35(1), 58–78.

Stoffel, E. M., McKernin, S. E., Brand, R., Canto, M., Goggins, M., Moravek, C., Nagarajan, A., Petersen, G. M., Simeone, D. M., Yurgelun, M., & Khorana, A. A. (2019). Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 37(2), 153–164.

Szender, J. B., Kaur, J., Clayback, K., Hutton, M. L., Mikkelson, J., Odunsi, K., & Dresbold, C. (2018). Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. International Journal of Gynecological Cancer, 28(1), 26–33.

Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., Offit, K., & Robson, M. E. (2016). Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews. Clinical Oncology, 13(9), 581–588.

US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Jr, Kubik, M., Landefeld, C. S., Mangione, C. M., Pbert, L., Silverstein, M., Simon, M. A., Tseng, C. W., & Wong, J. B. (2019). Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 322(7), 652–665.

Walker-Smith, T. L., & Peck, J. (2019). Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment. Nursing for Women's Health, 23(6), 518–525.

Disclaimer

All information in Hereditary Cancer Syndromes: Are Your Patients at Risk? is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Hereditary Cancer Syndromes: Are Your Patients at Risk?. Reliance on any information in this program is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Hereditary Cancer Syndromes: Are Your Patients at Risk?